One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papershttps://doi.org/10.1016/j.annonc.2023.09.1927
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2023 |
 Citations: 1 |
Affiliation: Eisai (United States), Asan Medical Center, University of Ulsan, Agostino Gemelli University Polyclinic, University of Paris-Saclay, University of Rochester Medical Center, Sunnybrook Health Science Centre, Health Sciences Centre, Memorial Sloan Kettering Cancer Center, MSD (Switzerland), National Cancer Center Hospital East748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
